CLAIMS

1. Compounds where a ring structure (VIII)



VIII

representing a porphyrin, chlorin or bacteriochlorin/isobacteriochlorin ring in any of its imino-nitrogen tautomeric forms carries four aromatic preferably phenyl substituents Ar each themselves carrying one or more hydroxy groups, one or more of which hydroxy groups is in turn linked to an antibody directed against a cell surface antigen of cancer or other diseased cells.

2. Compounds according to claim 1 where the aromatic groups are m-hydroxy phenyl groups.

3. Compounds according to claim 1 or claim 2 where the antibody is linked to the aromatic hydroxy group through a linking group, suitably an ether linked group particularly:-



where n is 1 to 4 and A is –OH or –NH_2, or alternatively an ester-linked group particularly:-







where n and A are as before and R^1 is hydrogen or a hydrocarbon or carboxylated amino-acid side chain representing particularly glycine, alanine, lysine or glutamic acid.

4. As intermediates, compounds as set out in claim 3, but lacking the antibody.

5. Compounds according to claim 1, 2 or 3 wherein the antibody is an MAb, particularly mMAb 425 or an antibody to an antigen as listed herein.

6. Compounds according to claim 1,2 or 3, where VIII represents a porphyrin particularly m-THPP.

7. Compounds according to claim 1, 2 or 3 where VIII represents a chlorin

8. Compounds according to claim 7 where VIII represents m-THPC.

9. Compounds according to claim 7, where VIII represents a chlorin other than m-THPC, particularly p-THPC or o-THPC.

10. Compounds according to claim 1, 2 or 3, where VIII represents a bacteriochlorin or isobacteriochlorin, particularly m-THPB or m-THPiB.

11. The treatment of disease using an antibody conjugate according to any one of claims 1 to 3 or 5 to 10 or prepared from an intermediate according to claim 4.

12. Use of a compound according to any one of claims 1 to 3 or 5 to 10 or prepared from an intermediate according to claim 4, in the preparation of a medicament for PDT, and a medicament for PDT in which such a compound is incorporated in a pharmaceutical diluent or carrier in an amount to enable administration of an 0.1 to 5 mg/kg (7 to 350 mg related to a 70 kg adult and calculated as the m-THPC or other PDT active) unit dose of said compound to a person in need of same.